Clinical Trials Logo

Estrogen clinical trials

View clinical trials related to Estrogen.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06358014 Recruiting - Estrogen Clinical Trials

Assessment of the Improvement in Cognitive Levels of Postmenopausal Depression Patients by Estrogen

Start date: May 12, 2023
Phase: N/A
Study type: Interventional

After menopause, there is a certain tendency towards depression, with the risk of developing depression being about 3 to 4 times higher than before menopause. Additionally, postmenopausal women experience varying degrees of cognitive decline, which are closely associated with hormonal changes. Therefore, we should pay more attention to the cognitive levels of postmenopausal depression patients. Increasing evidence suggests that changes in cognitive function during menopause may be related to the effects of estrogen on cognitive function, and estrogen therapy can effectively improve cognitive decline. Estrogen is not only associated with cognitive symptoms after menopause, but estrogen intervention is also an adjunctive treatment for postmenopausal depression symptoms. There is a close relationship between cognitive levels and depression, as depression itself is accompanied by cognitive decline, and early cognitive decline can also manifest depressive symptoms. Therefore, the cognitive levels of postmenopausal depression patients are also worthy of further attention.This study is an 8-week randomized controlled trial. The subjects are patients with postmenopausal depression accompanied by cognitive decline, all of whom have undergone natural menopause for at least one year; with HAMD-17 scores ≥17 points; and MOCA scores ≤26 points. This study aims to recruit patients with postmenopausal depression accompanied by cognitive decline from the outpatient or inpatient departments of Beijing Anding Hospital, Capital Medical University. Patients who meet the inclusion criteria will be randomly assigned to the combination group and the control group using a random number method. The combination group will receive estrogen combined with SSRIs, while the control group will only receive Selective serotonin reuptake inhibitors (SSRIs) intervention. Patients' cognitive function and depressive symptoms will be assessed using scales at baseline, 2 weeks, 4 weeks, and the end of 8 weeks of treatment, and safety evaluations will be conducted. The primary efficacy endpoint is the change in MoCA scores from baseline to the end of the study. Secondary efficacy endpoints include changes in HAMD-17, modified Kupperman Scale, ADL Scale, and hormone levels from baseline to the end of the study. The safety of the study drug will be evaluated through adverse event reporting, clinical laboratory tests, and physical examinations.

NCT ID: NCT06067217 Recruiting - Clinical trials for Abnormal Uterine Bleeding

Comparative Study of Tranexamic Acid, Estrogen for Treatment AUB in DMPA Users

Start date: September 30, 2023
Phase: N/A
Study type: Interventional

Abnormal uterine bleeding is the most common problems to discontinue Depo-medroxyprogesterone acetate (DMPA) in Thailand. This clinical trial use to provide drug to stop abnormal uterine bleeding from DMPA

NCT ID: NCT06043310 Recruiting - Clinical trials for Cardiovascular Diseases

Estrogen and Microvascular Function

Start date: June 2, 2023
Phase:
Study type: Observational

The goal of this study is to learn how long-term use of estrogen affects blood vessels in healthy adults who were assigned male at birth. Participants will: - give one blood draw of 5 mL - have a camera placed under the tongue to take pictures of blood vessels - have 2 laser Doppler microdialysis catheters placed on the forearm to monitor blood vessels before and after local drug infusion Researchers will compare blood vessel function of those who take estrogen supplements to those who do not.

NCT ID: NCT04255160 Recruiting - Vasodilation Clinical Trials

Impact of Estradiol on Endothelial Function in Peri-Menopausal Women

Start date: October 1, 2020
Phase: Phase 4
Study type: Interventional

The purpose of this study is to identify the impact of estradiol (E2) on the mechanisms that regulate vascular endothelial function in peri-menopausal (PERI) women. This study is the first step in understanding factors contributing to endothelial dysfunction in women with advancing reproductive age and in response to E2 administration.